Obinutuzumab provides strong early responses in untreated MCLJune 17, 2019Lymphoma & Plasma Cell Disorders
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCLJune 17, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Triplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Four-drug combo bests triplet in newly diagnosed myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Antibody targeting ‘do not eat me’ signals is active in AML, MDSJune 11, 2019AMLMyelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
Inhibitor produces high response rate in relapsed/refractory FLJune 11, 2019Lymphoma & Plasma Cell Disorders
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCLJune 7, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapyJune 7, 2019Leukemia, Myelodysplasia, Transplantation
SC-PEG comparable to pegaspargase in young ALL/LL patientsJune 1, 2019ALLAggressive LymphomasLeukemia, Myelodysplasia, Transplantation
Low intensity bridging may be best path to CAR T in adult ALLJune 1, 2019ALLLeukemia, Myelodysplasia, Transplantation
Combo produces ‘best response rate’ after first relapse in kids with AMLJune 1, 2019AMLPediatricsLeukemia, Myelodysplasia, Transplantation
